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Wiskott–Aldrich Syndrome (WAS) is a severe X-linked Primary Immunodeficiency that
affects 1–10 out of 1 million male individuals. WAS is caused by mutations in the WAS
Protein (WASP) expressing gene that leads to the absent or reduced expression of the
protein. WASP is a cytoplasmic protein that regulates the formation of actin filaments in
hematopoietic cells. WASP deficiency causes many immune cell defects both in humans
and in the WAS murine model, the Was−/− mouse. Both cellular and humoral immune
defects in WAS patients contribute to the onset of severe clinical manifestations, in par-
ticular microthrombocytopenia, eczema, recurrent infections, and a high susceptibility to
develop autoimmunity and malignancies. Autoimmune diseases affect from 22 to 72%
of WAS patients and the most common manifestation is autoimmune hemolytic ane-
mia, followed by vasculitis, arthritis, neutropenia, inflammatory bowel disease, and IgA
nephropathy. Many groups have widely explored immune cell functionality in WAS partially
explaining how cellular defects may lead to pathology. However, the mechanisms under-
lying the occurrence of autoimmune manifestations have not been clearly described yet.
In the present review, we report the most recent progresses in the study of immune cell
function in WAS that have started to unveil the mechanisms contributing to autoimmune
complications in WAS patients.
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WISKOTT–ALDRICH SYNDROME: CELLULAR DEFECTS AND
CLINICAL MANIFESTATIONS
Wiskott–Aldrich Syndrome (WAS) is a rare X-linked Primary
Immunodeficiency (PID) that affects 1–10 out of a million male
individuals (Ochs and Thrasher, 2006), whose life expectancy is
about 15 years in severe cases (Imai et al., 2004). Affected patients
demonstrate both cellular and humoral immunodeficiency, high
susceptibility to infections, eczema, microthrombocytopenia, and
increased risk of autoimmune disorders and lymphomas (Bosti-
cardo et al., 2009). WAS is caused by defective expression of
WAS Protein (WASP), a key regulator of cytoskeletal organiza-
tion in hematopoietic cells (Figure 1). The WAS gene is located
on the X chromosome and encodes a 502 amino acid protein
(Derry et al., 1994), which is constitutively expressed in the
cytoplasm of hematopoietic cells (Kim et al., 2000). WASP is
present in an auto-inhibited conformation and its activation is
mainly induced by the binding with GTPase Cell division Cycle
42 (CDC42; Abdul-Manan et al., 1999). Other factors, such as the
Non-Catalytic region of tyrosine Kinase adaptor protein (NCK;
Tomasevic et al., 2007), and the phosphorylation of WASP tyro-
sine residue 291 (Y291) can activate WASP independently of
CDC42 (Cory et al., 2002; Badour et al., 2004). The binding of
Phosphatidylinositol-4,5-bisphosphate (PIP2) is also an impor-
tant regulator of WASP activation by inducing a stable acting form
(Imai et al., 1999). WASP, in the active form, binds the Actin-
Related Protein (ARP)2/3 complex, which gives rise to nucleation
of actin filaments at the side of pre-existing filaments, thus creating
a branching network of actin at the plasma membrane (Symons
et al., 1996; Machesky and Insall, 1998; Miki et al., 1998; Machesky
and Gould, 1999; Blanchoin et al., 2000; Pantaloni et al., 2000). The
activity of the ARP2/3 complex was shown to contribute to a vari-
ety of cellular functions, including change of cell shape, motility,
endocytosis, and phagocytosis (Welch and Mullins, 2002).
The severity of disease, measured on the basis of the classifica-
tion proposed by Zhu et al. (1997) and subsequently modified
(Ochs and Thrasher, 2006; Ochs et al., 2009), is schematically
reported in Table 1.
A score from one to two identifies patients affected from a
milder form of the disease, named X-Linked Thrombocytopenia
(XLT;Villa et al., 1995), and characterized by reduced expression of
full-length mutated protein and microthrombocytopenia. Local-
ized eczema and occasional respiratory infections, in addition to
microthrombocytopenia, identify score 2 of the disease. Patients
who develop microthrombocytopenia, associated with persistent
but therapy-responsive eczema or infections receive a score of 3,
whereas a score of 4 is given if eczema or infections do not respond
to treatments. Finally, score 5 is assigned to patients developing
autoimmunity or tumors.
Wiskott–Aldrich Syndrome gene mutations are scattered
throughout the entire length of the WAS gene, although some
hot spots have been identified (Ochs and Thrasher, 2006). Muta-
tions that abolish WASP expression are mainly associated with a
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FIGURE 1 | Wiskott–Aldrich syndrome structure and interacting
proteins. TCR, BCR, chemokine receptors, TLRs, integrins, and the Fc
receptor γ-chain can promote the release of GDP from Rho family
GTPases, allowing GTP to bind. In immune cells, the major Rho GTPase
is the Cell Division Cycle 42 (CDC42). The WASP-Homology 1 (WH1)
domain mediates the binding to WASP-Interacting Protein (WIP; Ramesh
et al., 1997). The Phosphatidylinositol-4,5-bisphosphate (PIP2) links to the
Basic (B) domain and stabilizes WASP active form. The binding of the
GTPase-Binding Domain (GBD) with CDC42 induces WASP activation
(Kolluri et al., 1996; Symons et al., 1996; Miki et al., 1998). The
proline-rich region (PPP) provides binding sites for the
Vasodilator-Stimulated Phosphoprotein (VASP), and also for SRC family
tyrosine kinases and SRC Homology 3 (SH3) domain-containing proteins
such as the adaptor proteins GRB2, FYN, PI3K, and NCK. The
Verprolin-homology (V) domain binds to actin monomers, and the
Cofilin-homology (C) and Acidic (A) domains bind to the Actin-Related
Protein (ARP)2/3 complex. The V/C/A region functions as the platform to
initiate actin polymerization (Park et al., 2010).
severe clinical phenotype (full blown WAS) and a life expectancy
below 20 years of age (Jin et al., 2004). On the contrary, missense
mutations, which result in residual expression of a full-length
point-mutated WASP, are often associated with XLT (Villa et al.,
1995; Notarangelo et al., 2002; Albert et al., 2010), correspond-
ing to a disease score of 0.5–2 and a longer life expectancy (Imai
et al., 2004). All patients harboring mutations in the WAS gene
are micro-thrombocytopenic, although intermittent X-Linked
Thrombocytopenia (iXLT) is observed in some patients with sub-
stantial protein expression (Notarangelo et al., 2002). Importantly,
up to 11% of patients can present somatic mosaicism due to spon-
taneous in vivo reversion of the original mutation or second-site
compensatory mutations that restore production of the WAS gene
product (Stewart et al., 2007). The revertant mutation can occur
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Table 1 | WAS scoring system according to Zhu et al. (1997), with subsequent refinements (Ochs andThrasher, 2006; Ochs et al., 2009).
Clinical scores iXLT XLT WAS
<1 1 2 3 4 5
Thrombocytopenia −/+ + + + + +
Small platelets + + + + + +
Eczema − − (+) + ++ (+)/+/++
Immunodeficiency − −/(+) (+) + + (+)/+
Infections − − (+) + +/++ (+)/+/++
Autoimmunity or malignancy − − − − − +
Scoring system:−, absent; (+), mild;+, present;++, present and severe. iXLT, intermittent X-linked thrombocytopenia;WAS,Wiskott–Aldrich syndrome; XLT, X-linked
thrombocytopenia.
at various stages of hematopoietic differentiation thus conferring
high selective advantage to revertant cells over mutated cell popu-
lations not expressing WASP. Although many reports describe the
occurrence of this phenomenon, it is still not clear whether the
presence of somatic mosaicism might correlate with a better clin-
ical course of the disease (Davis and Candotti, 2009; Trifari et al.,
2010).
Absence or residual WASP expression causes functional defects
in all immune cells (Figure 2).
The formation of the Immunological Synapse (IS) in T cells and
T Cell Receptor (TCR)-dependent activation (Dupre et al., 2002;
Trifari et al., 2006; Nikolov et al., 2010), the cytotoxic activity of
CD8+ T cells and Natural Killer (NK) cells (Orange et al., 2002;
de Meester et al., 2010) and the suppressor activity of Naturally
occurring Regulatory T (nTreg) cells (Adriani et al., 2007, 2011;
Humblet-Baron et al., 2007; Maillard et al., 2007; Marangoni et al.,
2007) are all impaired in WASP-deficient cells. Motility, adhesion
and migration of B cells are also defective (Westerberg et al., 2005;
Meyer-Bahlburg et al., 2008). Additionally, the lack of WASP affects
podosome formation (Burns et al., 2001; Calle et al., 2004), motil-
ity (Binks et al., 1998; de Noronha et al., 2005) and T cell priming
in Dendritic Cells (DCs; Pulecio et al., 2008; Bouma et al., 2011), as
well as podosome and phagocytic cup formation in macrophages
(Linder et al., 1999; Tsuboi and Meerloo, 2007). Invariant Natural
Killer T (iNKT) cell functionality (Astrakhan et al., 2009; Locci
et al., 2009), adhesion, and migration of neutrophils (Zhang et al.,
2006) are also altered in the absence of WASP. Moreover, WASP is
also involved in signal transduction (Figure 3). In particular, TCR-
dependent nuclear recruitment of Nuclear Factor of Activated T
cells (NFAT)-1 in CD4+ T cells and both NFAT-1 and NFAT-2
in CD8+ T cells are reduced in WAS patients and correlate with
defective Th1 cytokine production (Cianferoni et al., 2005; Trifari
et al., 2006). Additionally, WASP is involved in B Cell Receptor
(BCR) signaling by binding to the Src homology three domains
of several tyrosine kinases, such as the Bruton’s Tyrosine Kinase
(BTK; Cory et al., 1996; Sharma et al., 2009).
The most common finding in WAS patients is microthrombo-
cytopenia which causes frequent hemorrhages in more than 80%
of patients (Ochs, 2002; Imai et al., 2004) and severe bleeding
episodes that lead to death in 4–10% of patients (Sullivan et al.,
1994; Imai et al., 2004). The mechanism underlying thrombocy-
topenia is not completely understood. One possible explanation
could be an abnormal platelet clearance induced by an increased
exposure of phosphatidylserine on the outer plasma membrane of
WASP-deficient platelets (Shcherbina et al., 2009). Another mech-
anism of platelet reduction that needs to be investigated more
in detail, is the elimination mediated by autoimmune reaction.
In fact, the presence of platelet-associated antibodies in Was−/−
mice (Marathe et al., 2009) and in some patients has been reported
(Corash et al., 1985; Semple et al., 1997). The second most com-
mon manifestation in WAS patients is the eczema. It is observed in
80% of patients and its severity inversely correlates with the expres-
sion of WASP. Indeed, it has been shown that WAS patients with
residual WASP expression develop moderate or transient form
of the disease, whereas most of WASP-negative patients develop
severe, treatment-resistant eczema (Imai et al., 2004). High IgE
levels (more than 1000 IU/mL) were observed in 62% of WASP-
negative patients and in 25% of WASP-positive. Although higher
IgE levels may represent a possible cause of eczema, the correlation
between increased IgE levels and eczema has not yet been demon-
strated. WAS patients are highly susceptible to infections by bacte-
ria, viruses, and fungi (Imai et al., 2004). Of note, WASP-negative
patients are more frequently affected by bacterial infections (otitis
media, skin abscess, pneumonia, enterocolitis, meningitis, sepsis,
urinary tract infection, and others), viral infections (Herpes sim-
plex and Cytomegalovirus) and fungal infections (Candida spp.,
Aspergillus spp., and Pneumocystis carinii) as compared to WASP-
positive patients (Imai et al., 2004). Patients with clinically most
severe WAS develop malignancies and/or autoimmune manifes-
tations. Malignancies can affect adolescent and young adult WAS
patients more than infants (Sullivan et al., 1994; Imai et al., 2004).
Epstein–Barr virus (EBV)-positive B cell lymphoma is most fre-
quently reported, but also myelodysplasia can be observed in
some patients (Imai et al., 2004). Autoimmune complications
are frequently observed in WAS, affecting 22–72% of patients
(Dupuis-Girod et al., 2003; Imai et al., 2004). WAS patients with
autoimmune diseases constitute a high-risk group with poor prog-
nosis. Moreover, autoimmunity is associated with a higher risk of
a later development of tumors and an increased risk of mortality
(Sullivan et al., 1994). A better understanding of the mechanisms
underlying autoimmunity in WAS would be crucial for the devel-
opment of more effective therapies for the management of these
manifestations in WAS and could also provide new insights in the
pathogenesis of autoimmunity in PIDs.
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FIGURE 2 | Schematic view of cellular defects described in WASP-deficient cells. MΦ, Macrophage; Neut., Neutrophil.
AUTOIMMUNE MANIFESTATIONS IN WAS PATIENTS AND
CURRENT TREATMENTS
The most common autoimmune manifestation in WAS is
hemolytic anemia (36%), followed by vasculitis (including
cerebral vasculitis; 29%), arthritis (29%), neutropenia (25%),
inflammatory bowel disease (9%), and IgA nephropathy (3%).
Henoch–Schönlein-like purpura, dermatomyositis, recurrent
angioedema, and uveitis have also been reported in some patients
(Dupuis-Girod et al., 2003; Imai et al., 2004). Moreover, multiple
autoimmune manifestations can be observed. In most cases, and
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FIGURE 3 | Role of WASP inTCR and BCR signaling pathways. The
main signaling molecules (blue and green ovals) acting downstream of
TCR (A), BCR, and TLRs (B) are depicted. The red boxes indicate the main
pathways induced downstream of these receptors. The role of WASP in
these pathways is indicated by stars close to interacting molecules: red
stars show the interactions that are demonstrated, whereas the blue stars
with question marks show hypothetical involvement of WASP in TLR
signaling pathways.
in all cases of hemolytic anemia, the onset of autoimmune compli-
cations occurs early in life (0–5 years; Dupuis-Girod et al., 2003).
Interestingly, it has been recently found that Was−/− mice develop
proliferative glomerulonephritis with increased IgA in the serum
and IgA production by splenic B cells (Nikolov et al., 2010; Shimizu
et al., 2012). Moreover old Was−/−mice showed aberrant glycosy-
lation of IgA (Shimizu et al., 2012), feature that has been associated
to the development of nephropathy-like glomerular lesions with
IgA deposition (Nishie et al., 2007). Although these studies have
been performed on WAS mouse model, they clearly suggest a pos-
sible mechanism for the pathogenesis of glomerulonephritis in
WAS patients.
Clinical management of WAS patients is a significant chal-
lenge since, with the exception of Bone Marrow Transplantation
(BMT), most available therapies are not curative. Intravenous
immunoglobulins (IVIG) and antibiotic prophylaxis are often
used to reduce the risk of infections in WAS patients, but it is
not clear whether these treatments effectively reduce the incidence
of life-threatening infections (Conley et al., 2003). Splenectomy
significantly increases and often normalizes the platelet counts
(Corash et al., 1985; Mullen et al., 1993). However, it does not fully
overcome the risk of bleeding and further predisposes to sepsis,
obliging the patients to life-long antibiotic prophylaxis (Mullen
et al., 1993). Relapse of thrombocytopenia has been described
in a fraction of splenectomized WAS patients (Corash et al.,
1985; Dupuis-Girod et al., 2003). Of note, in some cases, throm-
bocytopenia was found to be autoantibody-mediated and also
associated with hemolytic anemia or cerebral vasculitis (Dupuis-
Girod et al., 2003). Therefore, splenectomy is indicated only in
severe cases, for which there is no prospect for other curative
interventions. Treatment with human recombinant Interleukin
2 (hrIL-2) appeared to be effective in reducing herpes virus
infections and improving dermatitis in a WAS patient (Azuma
et al., 1993). Administration of hrIL-2 ameliorated proliferation
of cultured T cells from one patient (Azuma et al., 2000) and
restored cytotoxicity and actin accumulation at the IS in NK
cells from another treated patient (Orange et al., 2011). Since
WAS T cells are less efficient in producing IL-2, NK cells do
not receive sufficient IL-2, thus resulting in reduced NK acti-
vation and failure to respond effectively to infections. A clinical
trial with hrIL-2 is currently ongoing in WAS (ClinicalTrials.gov
identifier NCT00774358). The treatment of choice for autoim-
mune manifestations in WAS patients consists of steroids, alone,
or in association with cyclosporine (Dupuis-Girod et al., 2003).
Steroids are the first-line treatment for all patients with hemolytic
anemia and efficiently induce remission in 10% of cases, are par-
tially effective in 60% of cases, while are ineffective in 30% of
cases. Cyclophosphamide and azathioprine are also used in some
cases and are effective in a small percentage of cases. Patients
with severe autoimmune thrombocytopenia after splenectomy are
usually treated with IVIG, high-dose steroids, azathioprine, and
cyclophosphamide. Other autoimmune or inflammatory compli-
cations are generally treated with steroids, in association with
cyclosporine, and are effective in the majority of skin vasculi-
tis, arthritis, bowel inflammatory disease and renal disease cases
(Dupuis-Girod et al., 2003). Anti-CD20 monoclonal antibody
therapy has been also performed for the treatment of autoim-
mune hemolytic anemia in some patients. This treatment results
effective in correcting the anemia, but it may need repeated courses
due to relapse of the disease (Ship et al., 2002; Kim et al., 2007).
Currently, the only resolutive therapeutic option for WAS
patients is BMT. When a Related HLA-Identical Donor (RID) is
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available, BMT leads to 73–100% survival (Mullen et al., 1993;
Ozsahin et al., 1996, 2008; Filipovich et al., 2001; Antoine et al.,
2003; Kobayashi et al., 2006; Pai et al., 2006; Moratto et al., 2011).
On the other hand, transplantation using the bone marrow of a
Mismatched Related Donor (MMRD) results in a poor survival
ranging from 29 to 52% (Mullen et al., 1993; Filipovich et al.,
2001; Kobayashi et al., 2006; Ozsahin et al., 2008). In addition, this
type of transplant is associated with an elevated risk of developing
life-threatening EBV+ lymphoproliferative syndrome, infections,
autoimmunity, and graft-versus-host disease (GVHD; Filipovich
et al., 2001), therefore it is not recommended except in case of
emergency. When a suitable related donor is missing, transplan-
tation using the bone marrow or cord blood from a Matched
Unrelated Donor (MUD) is a valid therapeutic option, leading to
71–81% survival (Filipovich et al., 2001; Kobayashi et al., 2006; Pai
et al., 2006). Two recent retrospective studies have analyzed long-
term outcome and donor cell engraftment in WAS patients who
have been treated by Hematopoietic Stem Cell Transplantation
(HSCT; Ozsahin et al., 2008; Moratto et al., 2011). They observed
that 20% of patients developed autoimmune manifestations after
HSCT independently of chronic GVHD (Ozsahin et al., 2008)
and some patients had more than one manifestation. Autoim-
mune manifestations appeared at a median of 1.5 years after HSCT
(range: 4 months to 10 years). The median duration of autoimmu-
nity was 4 years (range: 1–20 years). Autoimmune manifestations
were more frequent in recipients of MUD (28%) and MMRD
(26%) than RID HSCT (11%). Ozsahin and colleagues investi-
gated whether patients developing autoimmunity after HSCT had
autoimmune manifestations also before treatment. Overall, 17
patients had autoimmune manifestations before transplantation
that persisted thereafter in seven of them. Conversely, autoimmu-
nity occurred de novo in 11–23% of transplanted patients. A very
interesting observation in both retrospective studies was the strong
correlation between autoimmunity occurrence and the chimerism
pattern. Overall, incomplete reconstitution of lymphocyte counts
and incidence of autoimmunity were higher in patients with a
lower degree of chimerism in both lymphoid and myeloid com-
partments as compared to patients with full chimerism (Ozsahin
et al., 2008; Moratto et al., 2011).
A very promising alternative to HSCT, when a matched donor is
missing, is the infusion of gene corrected autologous Hematopoi-
etic Stem Cells (HSCs). Two different Gene Therapy (GT) clinical
trials have been approved: a Retroviral Vector (RV)-mediated gene
transfer (Boztug et al., 2010) and a LentiviralVector (LV)-mediated
GT approach, developed by our and other groups (Dupre et al.,
2006; Galy et al., 2008). In the RV-mediated clinical trial, sustained
expression of WASP in HSCs, lymphoid and myeloid cells, and
platelets was shown in two treated patients 3 years after GT (Boztug
et al., 2010). T and B cells, NK cells, and monocytes were also func-
tionally corrected resulting in improved clinical conditions. Signs
and symptoms of autoimmunity disappeared in both patients
within the first year after GT. In one of the two reported patients,
severe autoimmune hemolytic anemia, autoimmune thrombo-
cytopenia, and autoimmune neutropenia disappeared; whereas
severe eczema resolved in the second patient. However, in this
trial, leukemia occurred in one out of ten GT patients, prob-
ably due to insertional mutagenesis caused by RV integration
(Press Release, Hannover Medical School, http://www.asgct.org/
UserFiles/file/Genetherapy_WAS_final_english.pdf). This adverse
event gives rise to some concerns on the safety of RV-mediated GT
for WAS. A multicenter clinical trial using a third generation LV
carrying WAS gene driven by the endogenous promoter is on going
in Milan, Paris, and London. Preclinical data in the murine model
indicate that the LV-mediated GT approach is effective in restoring
immune cell functionality (Blundell et al., 2008; Marangoni et al.,
2009; Bosticardo et al., 2011; Catucci et al., 2011). GT treated
Was−/− mice did not show any adverse events or tumors even
in long-term follow up studies (Marangoni et al., 2009). Finally,
we and others demonstrated the efficacy of LV-mediated GT in
CD34+ cells obtained from WAS patients (Charrier et al., 2007;
Scaramuzza et al., 2012). Nevertheless, data from the clinical study
are needed to provide definitive evidence of the efficacy and safety
of this novel therapeutic approach.
REGULATION OF T CELL TOLERANCE IN WAS
T cells are significantly reduced in peripheral blood of WAS
patients and show a defective proliferation in response to TCR
stimulation by CD3-specific antibody, although this defect is
present only at low doses of agonistic antibody (Molina et al.,
1992, 1993). TCR-dependent activation in WASP-deficient T cells
results in a reduced IL-2 production (Molina et al., 1993), that is
associated with delayed NFAT-1 nuclear translocation and defec-
tive T-bet induction (Cianferoni et al., 2005; Trifari et al., 2006;
Taylor et al., 2010). T cell activation is regulated by the formation
of the IS, a polarized cluster of TCR, costimulatory molecules, sig-
naling molecules, and integrins at the T cell:antigen presenting cell
(APC) interface. To promote their lateral movement on the plasma
membrane, the molecules being recruited to the IS are associ-
ated with specific cholesterol-enriched membrane microdomains,
called lipid rafts. In the absence of WASP, IS can be formed only
after strong TCR stimulation (Cannon and Burkhardt, 2004). In
particular, WASP-deficient T cells fail to upregulate GM1 on the
cell surface, cluster GM1 in the lipid rafts during IS formation
(Dupre et al., 2002) and maintain IS stability after migration (Sims
et al., 2007).
It is commonly assumed that autoimmunity is a consequence of
the breakdown of central or peripheral tolerance to self-antigens.
nTreg cells are fundamental to maintain tolerance to self-antigens
and suppress excessive immune responses. nTreg cell develop-
ment and function depend on TCR signaling, together with CD28
recruitment, FOXP3 expression, and presence of IL-2 (Sakaguchi
et al., 2008). Several groups, including ours, have described the
defects of nTreg cells in WAS patients and Was−/− mice in local-
izing and suppressing T effector cell response (Adriani et al.,
2007; Maillard et al., 2007; Marangoni et al., 2007), although their
number in blood of WAS patients is comparable with healthy
donors (Marangoni et al., 2007). It is not clear whether a defec-
tive thymic development of Was−/− nTreg cells could account
for their impaired in vivo suppressive function, since one group
has shown reduced nTreg cell percentage in the thymus (Maillard
et al., 2007), while three other groups observed normal frequency
while showed a reduced function in vivo (Adriani et al., 2007;
Humblet-Baron et al., 2007; Marangoni et al., 2007), but all showed
a reduced in vivo suppression. Was−/− nTreg cell failure to control
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aberrant T cell activation has been also demonstrated in vivo in
a mouse model of autoimmunity (Humblet-Baron et al., 2007).
Moreover, selective advantage of WASP-expressing nTreg cells was
shown in a WAS patient with revertant mutation, demonstrating
that WASP has a role in nTreg cell fitness (Humblet-Baron et al.,
2007). Although the requirement of WASP for nTreg cell func-
tionality has been demonstrated, the role of WASP in these cells
is still unclear. Indeed, differently from effector T cells, WASP is
not recruited to the IS (Marangoni et al., 2007), thus suggesting
a possible role of WASP in TCR signaling of nTreg cells. More-
over, WASP-deficient nTreg cells are also defective in suppressing
B cell activation. In fact, it has been shown in in vitro studies that
nTreg cells from Was−/−mice are less efficient in turning off B cell
proliferation and this defect is associated with a reduced killing
of B cells and significantly decreased secretion of granzyme B by
nTreg cells (Adriani et al., 2011). Susceptibility of WAS patients to
develop autoimmune diseases can be at least in part explained by
nTreg cell dysfunction.
Recent findings have demonstrated that also T effector cells are
implicated in tolerance breakdown in WAS. Indeed, in response
to restimulation through the TCR, activated T cells can undergo
apoptosis, and this event is called restimulation-induced cell death
(RICD; Lenardo, 1991; Siegel et al., 2000). RICD process con-
tributes to the maintenance of peripheral immune tolerance by
eliminating T cells responding to prolonged presence of antigens,
such as self-antigens and persistent pathogen antigens (Critchfield
et al., 1994; Ettinger et al., 1995; Weant et al., 2008). In CD4+ T
cells, RICD is induced by the Tumor Necrosis Factor (TNF) family
member Fas ligand (FasL) that is released and binds its recep-
tor Fas in an autocrine fashion (Critchfield et al., 1994; Ettinger
et al., 1995; Siegel et al., 2000; Green et al., 2003; Weant et al., 2008).
Nikolov and colleagues have shown that WASP is required for T cell
apoptosis by RICD. In the absence of WASP, the release of FasL by
CD4+ T cells is reduced and this is associated to a decreased TCR-
mediated apoptosis (Nikolov et al., 2010). Together with nTreg cell
defects, these recent findings highlight the role played by effector
T cells in the maintenance of T cell tolerance in WAS.
REGULATION OF B CELL TOLERANCE IN WAS
In the last years, many studies have assessed the role of B cells
in driving autoimmune diseases such as Rheumatoid Arthritis
(RA), Multiple Sclerosis (MS), and Systemic Lupus Erythematosus
(SLE; Townsend et al., 2010). These data revealed the complex role
of B cells that work independently or synergistically with other
components of the innate and adaptive immune system to drive
autoimmune pathogenesis.
For many years, the functionality of B cells in WAS patients
was poorly investigated. The presence of a skewed distribution of
serum Ig isotypes (reduced IgM, normal IgG, and elevated IgE
and IgA levels) and a reduced or absent antibody production to
polysaccharides and other T cell-independent antigens (Golding
et al., 1984; Ochs and Thrasher, 2006) represent the first evi-
dences of a defective B cell effector function in WAS patients. This
prompted many researchers to investigate more in detail the B
cell compartment in WAS, mainly taking advantage of the murine
model of the disease (Was−/− mice). In the last decade, it has
been clearly defined that the lack of WASP causes defects in the
cytoskeletal functions of B cells, including adhesion, migration,
and homing (Westerberg et al., 2005, 2008; Meyer-Bahlburg et al.,
2008). These defects may compromise the capacity of B cells to be
properly activated and reach the site of infection contributing to
the inability of the immunodeficient host to completely eradicate
infectious agents. In this respect, it has been accepted, in particu-
lar for PIDs, that chronic immune response due to an incomplete
pathogen clearance may favor breakdown of peripheral tolerance.
Of note, the complement receptors CD21 (CR2) and CD35 (CR1)
are expressed at lower levels on B cells of patients with WAS (Park
et al., 2005) contributing to a suboptimal B cell capacity to capture
and present opsonized antigens. Additionally, given the critical
role of CD21 and CD35 in the negative selection of self-reactive
B cells (Prodeus et al., 1998), the altered expression or function
of these receptors may affect the maintenance of B cell tolerance
in Immune Complex (IC)-mediated autoimmune diseases such as
SLE and RA (Erdei et al., 2009).
The fate of self-reactive B cells within the bone marrow and
peripheral lymphoid compartment is largely determined by the
strength of signal mediated by BCR in response to antigen cross-
linking (Nemazee and Burki, 1989; Erikson et al., 1991; Goodnow,
1996). To this regard, reports of a defective BCR activation are
controversial. Activation of WASP-deficient B cells was found to
be defective after BCR engagement in terms of calcium mobi-
lization in primary B cells isolated from WAS patients and also
in WASP-deficient EBV-transformed B cell lines (Simon et al.,
1992). However, this defect was not confirmed by Henriquez et al.
(1994). More recently, studies performed on Was−/−mice showed
a normal proliferative response of B cells after stimulation with
anti-IgM, LPS, or anti-CD40 (Snapper et al., 1998; Zhang et al.,
1999) and a normal or increased class switch (Westerberg et al.,
2005). However, the presence of circulating autoantibodies in
WAS patients (Dupuis-Girod et al., 2003; Schurman and Candotti,
2003) and in Was−/− mice (Humblet-Baron et al., 2007; Nikolov
et al., 2010; Becker-Herman et al., 2011; Bosticardo et al., 2011)
represents the first evidence of a perturbed B cell tolerance. Very
recently, two studies have shown the contribution of B cell intrin-
sic defects to the pathogenesis of autoimmunity in two different
murine models. Indeed, Becker-Herman et al. (2011) observed
that female Was+/− mice generate anti-nuclear antibodies at rates
and titers equivalent to Was−/− mice even though heterozygous
animals have a normal nTreg cell compartment. Based on this evi-
dence, they demonstrated in mixed BM chimeras, in which only B
cells lacked WASP expression, that the selective defect in B cells is
sufficient for the generation of autoantibodies. Additionally, they
suggested that BCR/Toll-Like Receptor (TLR) co-engagement in
Was−/− B cells from chimeras could mediate tolerance breakdown,
since the loss of Myeloid Differentiation primary response gene
88 (MyD88) signaling abolished the production of anti-dsDNA
antibodies, germinal center formation, and development of sys-
temic autoimmune disease (Becker-Herman et al., 2011). More
recently, by conditional WAS gene deletion in B cells (B/WcKO
mice), Recher et al. (2012) observed that WASP deficiency limited
to B cells is sufficient to promote autoantibody production and
kidney tissue damage in B/WcKO mice.
Overall, these findings highlight the contribution of B cells to
the pathogenesis of autoimmunity in WAS and suggest that the B
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cell autonomous defect could represent a sufficient factor to break
tolerance in WAS. However, in addition to the supposed role for
TLR signaling in the autoreactivity of Was−/− B cells, other mech-
anisms are potentially involved and need to be further investigated
both in mice and humans.
FUTURE DIRECTIONS
WAS is characterized by a very complex spectrum of cellular
defects, many of which can predispose patients to the development
of autoimmunity (Figure 4).
As described above, defective control of the strength of immune
response by nTreg cells, the presence of autoantibodies and poten-
tially autoreactive B cells have been demonstrated in WAS (Bosti-
cardo et al., 2009). However several mechanisms shown to be
involved in the pathogenesis of autoimmune diseases still need
to be investigated in WAS. iNKT cells have been shown to prevent
autoimmune disease in a mouse model of experimental Autoim-
mune Encephalomyelitis (EAE; Miyamoto et al., 2001; Singh et al.,
2001) and uveitis (Oh et al., 2011). Although the mechanisms
have not been fully understood, it has been shown that iNKT
activation reduces autoimmune symptoms by limiting the devel-
opment of Th17 cells in a cell contact- and cytokine-dependent
manner (Mars et al., 2009). Moreover, in mice, iNKT cells sup-
press anti-DNA antibody production and reduce autoreactive B
cells (Yang et al., 2011), whereas iNKT reduction leads to increased
autoreactive B cell activation (Wermeling et al., 2010). Since iNKT
cells are reduced in WAS patients and functionally defective in
Was−/− mice (Astrakhan et al., 2009; Locci et al., 2009) it can
be hypothesized that such impairment may also contribute to
autoimmunity.
A mechanism contributing to the tolerance breakdown in PIDs
is related to the inability of innate immune cells, in particular DCs,
to properly activate adaptive immune response (Arkwright et al.,
2002). Since DCs have a role in the induction of nTreg cells (Mani-
cassamy and Pulendran,2011) and DCs lacking WASP are defective
in T cell priming (Bouma et al., 2007; Pulecio et al., 2008), it is
FIGURE 4 | Schematic view of immunodeficiency and
autoimmunity in WAS. The impairment of both innate and adaptive
immune systems is responsible of immunodeficiency (blue box) and
autoimmunity (red box) in WAS. Immune cell defects described in
WASP-deficient cells are shown in red. The incomplete pathogen
clearance is sustained by cytoskeleton and functional defects of
macrophages, DCs, T cells, B cells, and their defective interactions. The
reduced expression of CD21 and CD35, two complement receptors
involved in antigen uptake and presentation and also in negative
selection of self-reactive B cells, places B cells at the interface
between immunodeficiency and autoimmunity. Defective suppression
of WASP-deficient nTreg cells toward both T and B cells contributes to
the tolerance breakdown in WAS. Defect in RICD process, resulting in
defective effectorT cell apoptotic death afterTCR restimulation, concurs
in the persistence of T cell response to pathogens or self-antigens.
Additionally, intrinsic B cell defects contribute to autoimmunity in WAS,
probably via a TLR-mediated mechanism. Dashed lines represent
hypothetical mechanisms involved in WAS-related autoimmunity. MHC,
Major Histocompatibility Complex; RICD, Restimulation-Induced Cell
Death; autoAbs, autoantibodies; Ag, Antigen.
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possible to hypothesize that a defect in nTreg cell induction by DCs
might occur in the absence of WASP. Immunodysregulation can be
also sustained by overload of pathogen antigens or apoptotic mate-
rial due to defective clearance by innate immune cells. Antigen
overload in fact results in a prolonged immune response, which
promotes expansion of Th17 cell subset, playing a central role in
many autoimmune diseases, such as MS, RA, and Crohn’s disease
(Langrish et al., 2005; Fouser et al., 2008; Isaksson et al., 2009;
Sharma et al., 2009). Furthermore, reduced clearance of apoptotic
material has been associated to the accumulation of autoantibod-
ies in SLE (Gaipl et al., 2005; Fransen et al., 2012). WASP-deficient
DCs are impaired in antigen uptake and migration to secondary
lymphoid tissues (Westerberg et al., 2003; de Noronha et al., 2005)
suggesting an inefficient pathogen clearance, process that needs to
be investigated in in vivo models of infection. Moreover, WASP-
deficient macrophages are less efficient in uptaking apoptotic cells
both in vitro and in vivo (Leverrier et al., 2001). All together, these
findings suggest that dysregulation of Th17 cell activation might
contribute to autoimmunity induction in WAS patients, although
no evidence has been provided so far to sustain such hypothesis.
Recent studies have demonstrated the key role played by a spe-
cific subset of DCs, namely plasmacytoid DCs (pDCs), in the
pathogenesis of systemic autoimmune diseases. In particular, IFN-
α produced by pDCs upon recognition of foreign nucleic acids via
TLR7 and TLR9 contributes to tolerance breakdown in several
autoimmune diseases, such as SLE, SS, and psoriasis (Ronnblom,
2011). In these clinical settings, self-nucleic acid-containing ICs
trigger TLR7 or TLR9 leading to an uncontrolled pDCs activation.
In PIDs, an increased susceptibility to viral infection, in combina-
tion with a defective clearance of pathogens, could be the triggering
factor of the over-activation of type I IFN pathway. Moreover, cell
death induced by viral infection leads to the release and accumula-
tion of self-antigens in the extracellular matrix. Since PID patients,
including WAS patients, are highly susceptible to infections and
fail to completely eradicate the pathogens, high levels of ICs and
activation of the type I IFN system can be expected. Furthermore,
increasing evidences highlight the role played by neutrophils in
SLE in the induction of type I IFN production. Mature neutrophils
are primed in vivo by type I IFN and die upon exposure to anti-
ribonucleoprotein antibodies, releasing neutrophil extracellular
traps (NETs) which in turn activate pDCs to produce high lev-
els of type I IFN (Garcia-Romo et al., 2011). Overall, these studies
have demonstrated an important role of neutrophils and pDCs in
promoting autoimmune diseases and it can be envisaged that these
mechanisms may act in the complexity of WAS autoimmunity.
Triggering of autoreactive B cells by self-nucleic acid-
containing ICs can be another possible mechanism underlying
the production of autoantibodies in WAS. In fact, it is known
that self-nucleic acid-containing ICs can activate B cells through
synergistic engagement of BCR and TLR7 or TLR9 (Leadbetter
et al., 2002; Lau et al., 2005; Chaturvedi et al., 2008), and the loss
of MyD88 signaling in Was−/− mice abolish the production of
anti-dsDNA antibodies (Becker-Herman et al., 2011). The recent
findings of B cell intrinsic defect (Becker-Herman et al., 2011;
Recher et al., 2012) open a new scenario in tolerance breakdown
in WAS although the underlying mechanisms are still unclear. It
is known that B cell tolerance is established through central and
peripheral checkpoints during B cell maturation which require
proper BCR and TLR signaling together with extrinsic factors
(Meffre, 2011). The cytoskeleton controls the distribution of the
BCR and shapes its signaling (Batista et al., 2010). In particular, the
density of actin network inversely correlates with the rate of BCR
diffusion and the restriction of BCR diffusion limits signaling.
Since WASP is required for actin polymerization and cytoskeletal
organization in B cells (Facchetti et al., 1998; Westerberg et al.,
2005), it is reasonable to speculate that the threshold of activation
might be altered in WASP-deficient B cells. In the bone marrow,
receptor editing is the major mechanism aimed at eliminating self-
reactive B cells during differentiation (Monroe and Dorshkind,
2007; von Boehmer and Melchers, 2010) by editing autoreactive
receptors through secondary rearrangements in light chain loci
(Halverson et al., 2004). Abnormal receptor editing is involved in
the loss of central B cell tolerance (Ng et al., 2004). Interestingly,
alterations in the regulation of secondary recombination events
have been reported in BTK-, Interleukin-1 Receptor-associated
Kinase 4 (IRAK4)-, and MyD88-deficient patients and in a group
of Common Variable Immunodeficiency (CVID) patients with
expanded autoreactive CD21−/low B cells (Ng et al., 2004; Isnardi
et al., 2008; Meffre, 2011). Given the interaction of WASP with BTK
(Cory et al., 1996; Sharma et al., 2009), the involvement of MyD88
signaling in B cell tolerance (Becker-Herman et al., 2011) and the
increased frequency of CD21− B cells in WAS patients (Park et al.,
2005), it would be worth to investigate whether receptor editing is
defective also in the absence of WASP. Furthermore, in the periph-
ery, survival of autoreactive B cells is supported by high levels of
BAFF and APRIL, members of the TNF superfamily, found to be
increased in several autoimmune diseases (Townsend et al., 2010)
and lymphopenic conditions (Cassani et al., 2010). This represents
an important mechanism involved in the regulation of peripheral
human B cell tolerance that would be interesting to investigate in
WAS. Finally, a new function as regulator of immune response has
been described for B cells and is mainly mediated by the secretion
of IL-10 (Matsushita et al., 2008; Yanaba et al., 2009; Watanabe
et al., 2010). Although the origin of regulatory B cells is unclear,
MZ B cells (Lenert et al., 2005; Evans et al., 2007) seem to have reg-
ulatory functions. Thus, considering the reduction of MZ B cells
in Was−/−mice (Westerberg et al., 2008; Bosticardo et al., 2011), it
would be interesting to investigate whether a defect in regulatory
B cell function is a factor contributing to autoimmunity.
In conclusion, together with the defects already described in the
literature, these future lines of enquiry underline the greater than
expected extent to which the WASP deficiency affects the immune
system. Further research is necessary to define the underlying mol-
ecular and cellular mechanisms leading to autoimmunity, which
represents the main collateral damage caused by WASP deficiency.
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